Secukinumab is a novel IL-17A inhibitor that has been confirmed to be effective for treating PsA and RA. Several studies have demonstrated that secukinumab also provides benefits for AS patients. Thus, we performed a meta-analysis of RCTs to evaluate the short-term efficacy and safety of secukinumab for the management of AS. The PubMed, Medline, Embase, Web of Science, and Cochrane Library databases were searched for RCTs published prior to March 2020 on the treatment of AS with secukinumab. The primary outcome was the ASAS20 response, and the secondary outcomes included the ASAS40 response, ASAS5/6 response, SF-36 PCS score, ASQoL score, and AEs. Dichotomous data were expressed as pooled RRs with 95% CIs, while continuous data were expressed as pooled MDs with 95% CIs. Subgroup analysis was conducted based on whether the AS patients previously underwent treatment with TNFi. A total of 4 RCTs with 1166 patients were included in our meta-analysis. At week 16, secukinumab 150 mg yielded significant improvements in the clinical response and patient-reported outcomes for AS patients. There was no increased risk of AEs. Consistent results were detected in the meta-analysis of secukinumab 75 mg versus a placebo. Furthermore, no significant difference was detected between the secukinumab 75 mg group and secukinumab 150 mg group. We concluded that secukinumab is effective for treating AS and generally well tolerated by AS patients in the short term, regardless of whether they previously underwent TNFi treatment. The superiority of secukinumab 150 mg over secukinumab 75 mg seems to be limited, since no significant difference in any endpoint was detected between the two groups.

中文翻译：

---

苏金单抗治疗强直性脊柱炎的短期疗效和安全性：随机对照试验的系统评价和荟萃分析

苏金单抗是一种新型 IL-17A 抑制剂，已被证实可有效治疗 PsA 和 RA。多项研究表明，苏金单抗也为 AS 患者带来益处。因此，我们对 RCT 进行了荟萃分析，以评估苏金单抗治疗 AS 的短期疗效和安全性。在 PubMed、Medline、Embase、Web of Science 和 Cochrane 图书馆数据库中搜索了 2020 年 3 月之前发表的关于使用苏金单抗治疗 AS 的随机对照试验。主要结果是 ASAS20 反应，次要结果包括 ASAS40 反应、ASAS5/6 反应、SF-36 PCS 评分、ASQoL 评分和 AE。二分数据表示为具有 95% CI 的汇总 RR，而连续数据表示为具有 95% CI 的汇总 MD。根据 AS 患者之前是否接受过 TNFi 治疗进行亚组分析。我们的荟萃分析共纳入了 4 项 RCT，共 1166 名患者。在第 16 周，苏金单抗 150 mg 显着改善了 AS 患者的临床反应和患者报告的结果。AE 的风险没有增加。在苏金单抗 75 毫克与安慰剂的荟萃分析中检测到一致的结果。此外，苏金单抗 75 mg 组和苏金单抗 150 mg 组之间未检测到显着差异。我们得出的结论是，苏金单抗对治疗 AS 是有效的，并且无论他们以前是否接受过 TNFi 治疗，AS 患者在短期内普遍耐受良好。苏金单抗 150 毫克优于苏金单抗 75 毫克似乎是有限的，